AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

uniQure N.V. (QURE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.12

-0.29 (-2.16%)

At close: Feb 20, 2025, 3:59 PM

12.90

-1.71%

After-hours: Feb 20, 2025, 05:26 PM EST

undefined% (undefined)

Bid	12.81
Market Cap	701.31M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.95
PE Ratio (ttm)	-2.65
Forward PE	n/a
Analyst	Strong Buy

Ask	12.99
Volume	229,443
Avg. Volume (20D)	2,279,288
Open	13.30
Previous Close	13.41
Day's Range	12.93 - 13.25
52-Week Range	3.73 - 19.18
Beta	undefined

About QURE

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 5, 2014

Employees 480

Stock Exchange NASDAQ

Ticker Symbol QURE

Website https://www.uniqure.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for QURE stock is "Strong Buy." The 12-month stock price forecast is $32, which is an increase of 143.83% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

uniQure N.V. is scheduled to release its earnings on Mar 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-9.75%

UniQure shares are trading lower after the company... Unlock content with Pro Subscription

2 months ago

+12.99%

UniQure shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $12 to $32.

News

1 day ago · seekingalpha.com

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial ...

2 weeks ago · benzinga.com

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dez...

2 months ago · fool.com

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's ...

2 months ago · zacks.com

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

2 months ago · zacks.com

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet

The consensus price target hints at a 228.1% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

2 months ago · zacks.com

What Makes uniQure (QURE) a New Buy Stock

uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.